390 related articles for article (PubMed ID: 35248866)
21. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Jänne PA; Yang JC; Kim DW; Planchard D; Ohe Y; Ramalingam SS; Ahn MJ; Kim SW; Su WC; Horn L; Haggstrom D; Felip E; Kim JH; Frewer P; Cantarini M; Brown KH; Dickinson PA; Ghiorghiu S; Ranson M
N Engl J Med; 2015 Apr; 372(18):1689-99. PubMed ID: 25923549
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
Mok T; Nakagawa K; Park K; Ohe Y; Girard N; Kim HR; Wu YL; Gainor J; Lee SH; Chiu CH; Kim SW; Yang CT; Wu CL; Wu L; Lin MC; Samol J; Ichikado K; Wang M; Zhang X; Sylvester J; Li S; Forslund A; Yang JC
J Clin Oncol; 2024 Apr; 42(11):1252-1264. PubMed ID: 38252907
[TBL] [Abstract][Full Text] [Related]
23. A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study.
Zhou Q; Wu L; Hu P; An T; Zhou J; Zhang L; Liu XQ; Luo F; Zheng X; Cheng Y; Yang N; Li J; Feng J; Han B; Song Y; Wang K; Zhang L; Fang J; Zhao H; Shu Y; Lin XY; Chen Z; Gan B; Xu WH; Tang W; Zhang X; Yang JJ; Xu X; Wu YL
Clin Cancer Res; 2022 Mar; 28(6):1127-1135. PubMed ID: 34740925
[TBL] [Abstract][Full Text] [Related]
24. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Yang JJ; Fang J; Shu YQ; Chang JH; Chen GY; He JX; Li W; Liu XQ; Yang N; Zhou C; Huang JA; Frigault MM; Hartmaier R; Ahmed GF; Egile C; Morgan S; Verheijen RB; Mellemgaard A; Yang L; Wu YL
Invest New Drugs; 2021 Apr; 39(2):477-487. PubMed ID: 33052556
[TBL] [Abstract][Full Text] [Related]
25. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
[TBL] [Abstract][Full Text] [Related]
26. CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
Kim DW; Kim SW; Camidge DR; Shu CA; Marrone KA; Le X; Blakely CM; Park K; Chang GC; Patel SP; Kar G; Cooper ZA; Samadani R; Pluta M; Kumar R; Ramalingam S
J Thorac Oncol; 2023 May; 18(5):650-656. PubMed ID: 36641093
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
Xiong A; Ren S; Liu H; Miao L; Wang L; Chen J; Li W; Li R; Wang X; Lu Z; Wang D; Wu X; Liu Z; Xing L; Mao Y; Liu C; Zeng A; Niu H; Du Y; Sun Y; Pan Y; Hu Y; Zhang X; Chen X; Ma Z; Li N; Zhang J; Zhao M; Li X; Ye F; Li M; Yu G; Zhang X; Min J; Han D; Li J; Zhou C
J Thorac Oncol; 2022 Oct; 17(10):1216-1226. PubMed ID: 35798241
[TBL] [Abstract][Full Text] [Related]
28. Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study.
Shi Y; Zhao Y; Yang S; Zhou J; Zhang L; Chen G; Fang J; Zhu B; Li X; Shu Y; Shi J; Zheng R; Wang D; Yu H; Huang J; Zhuang Z; Wu G; Zhang L; Guo Z; Greco M; Li X; Zhang Y
J Thorac Oncol; 2022 May; 17(5):708-717. PubMed ID: 35181498
[TBL] [Abstract][Full Text] [Related]
29. A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations.
Heymach J; Opdam F; Barve M; Gibson N; Sadrolhefazi B; Serra J; Yamamoto N
Clin Lung Cancer; 2023 Mar; 24(2):e65-e68. PubMed ID: 36528522
[TBL] [Abstract][Full Text] [Related]
30. Correlation Analysis between T790M Status and Clinical Characteristics of Patients with EGFR-sensitive Mutation Advanced NSCLC who Progressed after the First Generation and First-line EGFR-TKIs Administration: A Real-world Exploratory Study.
Zhen Y; Xu YB; Deng RY; Li M; Ma MT; Zhou ZG; Meng QJ; Gong YN; Zhao LY; Liu YB
Comb Chem High Throughput Screen; 2024; 27(6):845-853. PubMed ID: 37282652
[TBL] [Abstract][Full Text] [Related]
31. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.
Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Oki M; Tachihara M; Fujimoto D; Hayashi H; Yamaguchi K; Yamamoto S; Iwama E; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
Lung Cancer; 2023 Mar; 177():44-50. PubMed ID: 36731290
[TBL] [Abstract][Full Text] [Related]
32. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.
Duan J; Wu L; Yang K; Zhao J; Zhao Y; Dai X; Li M; Xie Y; Yao Y; Zhao M; Zhou C; Ren X; Liu Z; Pan Y; Li Y; Liu B; Cheng Y; Miao L; Yu Q; Zhang Z; Liu X; Cui J; Zhang Y; Zhang L; Li X; Li X; Shen B; Chen B; Zeng S; Li B; Hu Y; Li L; Wu R; Song Q; Wang J
J Thorac Oncol; 2024 Feb; 19(2):314-324. PubMed ID: 37776953
[TBL] [Abstract][Full Text] [Related]
33. A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.
Yu HA; Spira A; Horn L; Weiss J; West H; Giaccone G; Evans T; Kelly RJ; Desai B; Krivoshik A; Moran D; Poondru S; Jie F; Aoyama K; Keating A; Oxnard GR
Clin Cancer Res; 2017 Dec; 23(24):7467-7473. PubMed ID: 28954786
[No Abstract] [Full Text] [Related]
34. Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.
Park K; Jӓnne PA; Kim DW; Han JY; Wu MF; Lee JS; Kang JH; Lee DH; Cho BC; Yu CJ; Pang YK; Felip E; Kim H; Baek E; Noh YS
Cancer; 2021 May; 127(9):1407-1416. PubMed ID: 33434335
[TBL] [Abstract][Full Text] [Related]
35. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.
Peng P; Gong J; Zhang Y; Zhou S; Li Y; Han G; Meng R; Chen Y; Yang M; Shen Q; Chu Q; Xia S; Zhang P; Zhang L; Chen Y; Zhang L
Radiother Oncol; 2023 Jul; 184():109681. PubMed ID: 37105304
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study.
Zhang S; Yang L; Yang Y; Yang G; Xu H; Niu X; Wang Y
Cancer Med; 2023 Oct; 12(19):19438-19448. PubMed ID: 37723846
[TBL] [Abstract][Full Text] [Related]
37. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.
Tan DS; Leighl NB; Riely GJ; Yang JC; Sequist LV; Wolf J; Seto T; Felip E; Aix SP; Jonnaert M; Pan C; Tan EY; Ko J; Moody SE; Kim DW
Lancet Respir Med; 2020 Jun; 8(6):561-572. PubMed ID: 31954624
[TBL] [Abstract][Full Text] [Related]
39. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
40. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
